Vascular Biogenics’ (VBLT) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) in a report released on Tuesday. They currently have a $11.00 price target on the biopharmaceutical company’s stock.
Several other equities research analysts have also weighed in on VBLT. ValuEngine lowered Vascular Biogenics from a hold rating to a sell rating in a research report on Wednesday, September 27th. Zacks Investment Research cut Vascular Biogenics from a hold rating to a sell rating in a research note on Friday, August 18th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Vascular Biogenics has an average rating of Hold and a consensus price target of $12.90.
Shares of Vascular Biogenics (VBLT) traded up 2.049% during trading on Tuesday, reaching $6.225. 162,840 shares of the company’s stock were exchanged. The company’s 50-day moving average is $5.49 and its 200 day moving average is $5.18. The stock’s market capitalization is $168.13 million. Vascular Biogenics has a 52 week low of $3.90 and a 52 week high of $7.25.
Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. On average, analysts forecast that Vascular Biogenics will post ($0.74) earnings per share for the current year.
A hedge fund recently bought a new stake in Vascular Biogenics stock. KCG Holdings Inc. acquired a new position in shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 45,106 shares of the biopharmaceutical company’s stock, valued at approximately $248,000. KCG Holdings Inc. owned 0.17% of Vascular Biogenics at the end of the most recent quarter. Hedge funds and other institutional investors own 11.19% of the company’s stock.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Stock Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related stocks with our FREE daily email newsletter.